ABSTRACT

This invention relates to compounds of formula (I) or (II)



(I)



(II)

wherein, in either formula, independently;

R^1 and R^2 are the same or are different and are C_{1-8} alkyl, C_{2-8} alkylene, C_{3-8} cycloalkyl, aryl, heteroaryl, heterocycloalkyl, C_{3-6} cycloalkylaryl, or heterocycloaryl; wherein said alkyl, alkylene, cycloalkyl, aryl, heteroaryl, heterocyclyl, cycloalkylaryl, or heterocycloaryl are unsubstituted or substituted by one or more groups selected from the group consisting of halogen, C_{1-8} alkyl, C_{1-8}alkoxy, C_{1-8}thioalkoxy, cycloalkyl, aryl, heteroaryl, heterocycloalkyl, CF_3, SCF_3, $NHC(O)_nR^5$, $S(O)_mR^5$, $S(O)_2NR^5R^6$, $C(S)NR^5R^6$, $CONR^5R^6$, $C(O)_nR^5$;

n is 0, 1 or 2;

m is 0, 1 or 2;

R^5 is hydrogen, alkyl, aryl, alkylaryl, heterocycloalkyl, or heteroaryl and is unsubstituted or substituted by one or more groups selected from the group consisting of alkyl, C_{1-8}alkoxy, aryl, heteroaryl, halogen, NO_2, CN, N_3, SCF_3, and CF_3;

R^6 is hydrogen, alkyl, aryl, alkylaryl, heterocycloalkyl, or heteroaryl and is unsubstituted or substituted by one or more groups selected from the group consisting of alkyl, C_{1-8}alkoxy, aryl, heteroaryl, halogen, NO_2, CN, N_3, SCF_3, and CF_3, or when R^1 and/or R^2 contains $S(O)_2NR^5R^6$, $CONR^5R^6$, or $C(S)NR^5R^6$, then R^5R^6 together with the nitrogen may form a heterocyclic ring; or

a pharmaceutically acceptable salt or solvate thereof.